TUBERCULOSIS: PREVALENCE, RISK FACTORS, AND FIRST-LINE DRUG RESISTANCE
Introduction: In Kazakhstan, according to the National Center of Phthisiopulmonology, there has been a decrease in tuberculosis (TB) incidence, though the issue remains significant. TB is more common among socially vulnerable groups, including the homeless, prisoners, migrants, and individuals with weakened immune systems. The average TB incidence rate in the country is around 55 cases per 100,000 people, which is higher than the Central Asia average.
Aim of the literature review is to analyze TB prevalence worldwide and in Kazakhstan, with attention to key sociodemographic data, risk factors, and multidrug-resistant forms.
Search Strategy: After identifying primary keywords and synonyms, a literature search was conducted in English (PubMed, Google Scholar, Embase) and Russian databases (Cyberleninka, eLibrary), covering the past seven years for relevance. Selected publications underwent citation analysis, and abstracts were screened for relevance. Studies meeting inclusion criteria were then retrieved in full for detailed review. Inclusion criteria: studies pertinent to the topic, in English or Russian, published since 2017, including primary/secondary research, systematic reviews, meta-analyses, clinical guidelines, monographs, and conference abstracts.
Results and Conclusion: According to the World Health Organization (WHO), over 10 million new active TB cases are recorded annually. In Kazakhstan, the TB incidence rate in 2022 was 78 cases per 100,000 population. Although TB incidence has been decreasing in the country, the disease burden remains significant, particularly within specific regions and population groups. In 2019, Kyzylorda Region reported the highest incidence at 115 per 100,000, while the lowest rate, 55 per 100,000, was observed in Karaganda Region and its surrounding areas. These disparities may be due to differences in income, living conditions, population age, and comorbidities. A critical issue also remains the prevalence of multidrug-resistant TB (MDR-TB): approximately 25% of new cases and nearly 50% of previously treated patients are resistant to first-line medications. The government of Kazakhstan is actively working to combat TB, achieving significant progress in reducing prevalence and improving treatment outcomes.
Assiya A. Kussainova1, https://orcid.org/0000-0002-5738-0804
Assylkhan B. Adilzhanov2,3,
Maksat S. Adilgozhin3,
Gulnar M. Shalgumbayeva2, https://orcid.org/0000-0003-3310-4490
Gulmira A. Derbissalina1, https://orcid.org/0000-0003-3704-5061
Zhanagul B. Bekbergenova1, https://orcid.org/0000-0002-6146-3784
Ayagyoz T. Umbetzhanova1, https://orcid.org/0000-0002-2682-1689
Dana K. Kozhakhmetova2, https://orcid.org/0000-0002-8367-1461
Madiana S. Zhokebaeva2,
Timur M. Shamshudinov4, https://orcid.org/0000-0001-5015-871X
Laura T. Kassym1*, https://orcid.org/0000-0003-4448-6455
Арингазина А.М., Айтамбаева Н.Н., Назарова Л.З., Алимбекова Г.Т., Исмаилов Ш.Ш., Аденов М.М., Джазыбекова П.М., Мусабекова Г.А., Аликеева Э.А. Уровень осведомленности в вопросах туберкулеза населения и ключевых групп Республики Казахстан. Наука и Здравоохранение. 2021. 5(Т.23). С. 67-77. doi 10.34689/SH.2021.23.5.008
2. Гергерт В.Я., Авербах М.М., Эргешов А.Э. Иммунологические аспекты патогенеза туберкулеза. Терапевтический архив. 2019. 91 (11). C. 90-97.
3. Кондрашов В.А., Пугачева М.Г., Щапкова М.М. Туберкулез: патогенетические механизмы развития. Science Time. 2019. (8 (68)). C. 31-34.
4. Agonafir M., Belay G., Maningi N.E., Feleke A., Reta M.A., Olifant S.L., Hassen M.S., Girma T., Fourie P.B. Genetic diversity of Mycobacterium tuberculosis isolates from the central, eastern and southeastern Ethiopia. Heliyon. 2023. 9(12):e22898. doi: 10.1016/j.heliyon.2023.e22898.
5. Ahimbisibwe I., Tumusiime C., Muteebwa L., Mupere E., Andia Biraro I. Prevalence of pulmonary tuberculosis among casual labourers working in selected road construction sites in central Uganda. PLoS One. 2024. 19(6):e0304719. doi: 10.1371/journal.pone.0304719.
6. Aliyu G., El-Kamary S.S., Abimiku A., Blattner W., Charurat M. Demography and the dual epidemics of tuberculosis and HIV: Analysis of cross-sectional data from Sub-Saharan Africa. PLoS ONE. 2018. 13(9): e0191387. https://doi.org/ 10.1371/journal.pone.0191387
7. Ashaba C., Musoke D., Wafula S.T., Konde-Lule J. Stigma among tuberculosis patients and associated factors in urban slum populations in Uganda. Afr Health Sci. 2021. 21(4):1640-1650. doi: 10.4314/ahs.v21i4.18.
8. Available at: https://www.aidsdatahub.org/sites/default/files/resource/who-consolidated-guidelines-drug-resistant-tuberculosis-treatment-2019.pdf (Accessed 2019)
9. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531408/ (Accessed 2018)
10. Available at: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy (Accessed 16 December, 2022)
11. Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (Accessed 7 November, 2023)
12. Available at: https://www.worldbank.org/en/country/kazakhstan/overview (Accessed January 4, 2024).
13. Barberis I., Bragazzi N.L., Galluzzo L., Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. J Prev Med Hyg. 2017. 58(1):E9-E12.
14. Barry M. Prevalence of Latent Tuberculosis Infection in the Middle East and North Africa: A Systematic Review. Pulm Med. 2021. 6680651. doi: 10.1155/2021/6680651.
15. Behr M.A., Edelstein P.H., Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ. 2019. 367. l5770.
16. Belew H., Wubie M., Tizazu G. et al. Predictors of tuberculosis infection among adults visiting anti-retroviral treatment center at east and west Gojjam, northwest, Ethiopia, 2017 // BMC Infect Dis. 2020. 20. 593. https://doi.org/10.1186/s12879-020-05290-2
17. Bloom B.R., Atun R., Cohen T., Dye C., Fraser H., Gomez G.B., Knight G., Murray M., Nardell E., Rubin E., Salomon J., et al. editors. Major Infectious Diseases. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development. The World Bank. 2017. Chapter 11. PMID: 30212088.
18. Carabalí-Isajar M.L., Rodríguez-Bejarano O.H., Amado T., Patarroyo M.A., Izquierdo M.A., Lutz J.R., Ocampo M. Clinical manifestations and immune response to tuberculosis. World J Microbiol Biotechnol. 2023. 39(8). 206. doi: 10.1007/s11274-023-03636-x.
19. Chai Q., Wang L., Liu C.H., Ge B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell Mol Immunol. 2020. 17(9). 901-913. doi: 10.1038/s41423-020-0502-z.
20. Chakhaia T., Blumberg H.M., Kempker R.R., Luo R., Dzidzikashvili N., Chincharauli M., Tukvadze N., Avaliani Z., Stauber C., Magee M.J. Lack of weight gain and increased mortality during and after treatment among adults with drug-resistant tuberculosis in Georgia, 2009-2020. medRxiv [Preprint]. 2024. 2024.08.05.24311499. doi: 10.1101/2024.08.05.24311499.
21. Cohen K.A., Manson A.L., Desjardins C.A. et al. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med. 2019. 11. 45. https://doi.org/10.1186/s13073-019-0660-8
22. Cohen S.B., Gern B.H., Delahaye J.L., et al. Alveolar macrophages provide an early mycobacterium tuberculosis niche and initiate dissemination. Cell Host Microbe. 2018. 24. 439–46 e4.
23. Cohen S.B., Gern B.H., Urdahl K.B. The Tuberculous Granuloma and Preexisting Immunity. Annual review of immunology. 2022. 40. 589–614. https://doi.org/10.1146/annurev-immunol-093019-125148
24. Daniyarov A., Molkenov A., Rakhimova S., Akhmetova A., Yerezhepov D., Chingissova L., Bismilda V., Toksanbayeva B., Rakisheva A., Akilzhanova A., Kozhamkulov U., Kairov U. Genomic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Strains From Patients in Kazakhstan. Front Genet. 2021. 12. 683515. doi: 10.3389/fgene.2021.683515.
25. Darisheva M., Tracy M., Terlikbayeva A., Zhussupov B., Schluger N., McCrimmon T. Knowledge and attitudes towards ambulatory treatment of tuberculоsis in Kazakhstan. BMC Health Serv Res. 2020. 20(1). 563. doi: 10.1186/s12913-020-05413-0.
26. Dheda K., Cox H., Esmail A., Wasserman S., Chang K.C., Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology. 2018. 23(1). 36-45. doi: 10.1111/resp.13143.
27. Dohál M., Porvazník I., Solovič I., Mokrý J. Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine. Front Microbiol. 2023. 14. 1225438. doi: 10.3389/fmicb.2023.1225438.
28. Duarte R., Lönnroth K., Carvalho C., Lima F., Carvalho ACC., Muñoz-Torrico M., Centis R. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018. 24(2). 115-119. doi: 10.1016/j.rppnen.2017.11.003.
29. Ehrt S., Schnappinger D., Rhee K.Y. Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis. Nat Rev Microbiol. 2018. 16(8). 496-507. doi: 10.1038/s41579-018-0013-4.
30. Escombe A., Ticona E., Chávez-Pérez V. et al. Improving natural ventilation in hospital waiting and consulting rooms to reduce nosocomial tuberculosis transmission risk in a low resource setting. BMC Infect. 2019. 19. 88. https://doi.org/10.1186/s12879-019-3717-9
31. Espinal M.A., Peréz E.N., Baéz J., Hénriquez L., Fernández K., Lopez M., Olivo P., Reingold A.L. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet. 2000. 355(9200). 275-80. doi: 10.1016/S0140-6736(99)04402-5.
32. Falzon D., Zignol M., Bastard M., Floyd K., Kasaeva T. The impact of the COVID-19 pandemic on the global tuberculosis epidemic. Front Immunol. 2023. 14. 1234785. doi: 10.3389/fimmu.2023.1234785.
33. Ferluga J., Yasmin H., Al-Ahdal M.N., Bhakta S., Kishore U. Natural and trained innate immunity against Mycobacterium tuberculosis. Immunobiology. 2020. 225(3). 151951. doi: 10.1016/j.imbio.2020.151951.
34. Froeling F., Chen J., Meliefste K., Oldenwening M., Lenssen E., Vermeulen R., Gerlofs-Nijland M., van Triel J., Woutersen A., de Jonge D., Groenwold H., Bronsveld P., van Dinther D., Blom M. CHARRED Citizen Scientists; Hoek G. A co-created citizen science project on the short term effects of outdoor residential woodsmoke on the respiratory health of adults in the Netherlands. Environ Health. 2024. 23(1). 90. doi: 10.1186/s12940-024-01124-9.
35. Furin J., Cox H., Pai M. Tuberculosis. Lancet. 2019. 393(10181). 1642-1656. doi: 10.1016/S0140-6736(19)30308-3.
36. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024. 403(10440). 2133-2161. doi: 10.1016/S0140-6736(24)00757-8.
37. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. 2020. n. pag.
38. Gopalaswamy R., Shanmugam S., Mondal R., Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. 2020. 27(1). 74. doi: 10.1186/s12929-020-00667-6.
39. Haley C.A., Schechter M.C., Ashkin D., et al. BPaL Implementation Group. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clin Infect Dis. 2023. 77(7). 1053-1062. doi: 10.1093/cid/ciad312.
40. Johansen M.D., Kasparian J.A., Hortle E., Britton W.J., Purdie A.C., Oehlers S.H. Mycobacterium marinum infection drives foam cell differentiation in zebrafish infection models. Dev Comp Immunol. 2018. 88. 169-172. doi: 10.1016/j.dci.2018.07.022.
41. Kato Y., Ihara H., Takei S., Nakamura A., Fujimoto Y., Handoh T., Kurokawa K., Arai Y., et al. Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species. J Clin Tuberc Other Mycobact Dis. 2024. 36. 100464. doi: 10.1016/j.jctube.2024.100464.
42. Kebede A.H., Mamo H. Multidrug-resistant tuberculosis treatment outcomes and associated factors at Yirgalem General Hospital, Sidama Region, South Ethiopia: a retrospective cohort study. BMC Pulm Med. 2024. 24(1). 527. doi: 10.1186/s12890-024-03350-w.
43. Khan A., Singh V. K., Hunter R. L., Jagannath C. Macrophage heterogeneity and plasticity in tuberculosis. Journal of leukocyte biology. 2019. 106(2). 275–282. https://doi.org/10.1002/JLB.MR0318-095RR
44. Klautau G.B., da Mota NVF., Salles MJC., Burattini M.N., Rodrigues D.S. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study. BMC Infect Dis. 2018. 18(1). 585. doi: 10.1186/s12879-018-3508-8.
45. Korhonen V., Kivelä P., Haanperä M., Soini H., Vasankari T. Multidrug-resistant tuberculosis in Finland: treatment outcome and the role of whole-genome sequencing. ERJ Open Res. 2022. 8(4). 00214-2022. doi: 10.1183/23120541.00214-2022.
46. Lerner T.R., Queval C.J., Lai R.P., et al. Mycobacterium tuberculosis cords within lymphatic endothelial cells to evade host immunity. JCI Insight. 2020. 5. DOI:10. 1172/jci.insight.136937.
47. Liu X., Yang M., Xu P., Du M., Li S., Shi J., Li Q., Yuan J., Pang Y. Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9/CXCL10 axis in tuberculosis. Cell Mol Immunol. 2024. doi: 10.1038/s41423-024-01230-1.
48. Luies L., du Preez I. The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications. Clin. Microbiol. Rev. 2020. 33:e00036-20. doi: 10.1128/CMR.00036-20.
49. Marrella V., Nicchiotti F., Cassani B. Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair. Int J Mol Sci. 2024. 25(7). 4051. doi: 10.3390/ijms25074051.
50. Mbewana Ntshanka N.G., Msagati T.A.M. Trends and Progress on Antibiotic-Resistant Mycobacterium tuberculosis and Genes in relation to Human Immunodeficiency Virus. Can J Infect Dis Med Microbiol. 2023. 2023:6659212. doi: 10.1155/2023/6659212.
51. Melsew Y.A., Doan T.N., Gambhir M., Cheng A.C., McBryde E., Trauer J.M. Risk factors for infectiousness of patients with tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2018. 146(3). 345-353. doi: 10.1017/S0950268817003041.
52. Menzies N.A., Allwood B.W., Dean A.S., Dodd P.J., Houben RMGJ., James L.P., Knight G.M., Meghji J., Nguyen L.N., Rachow A., Schumacher S.G., Mirzayev F., Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nat Commun. 2023. 14(1). 6182. doi: 10.1038/s41467-023-41937-9.
53. Mishra S., Saito K. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and their in vitro study: A review. Front Cell Infect Microbiol. 2022. 12. 1029111. doi: 10.3389/fcimb.2022.1029111.
54. Murphy M.E., Wills G.H., Murthy S., Louw C., Bateson AL.C, Hunt R.D., McHugh T.D., et al. REMoxTB consortium. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study. BMC Med. 2018. 16(1). 189. doi: 10.1186/s12916-018-1169-5.
55. Obore N., Kawuki J., Guan J., Papabathini S.S., Wang L. Association between indoor air pollution, tobacco smoke and tuberculosis: an updated systematic review and meta-analysis. Public Health. 2020. 187. 24-35. doi: 10.1016/j.puhe.2020.07.031.
56. Ocaña-Paredes B., Rivera-Orellana S., Ramírez-Sánchez D., Montalvo-Guerrero J., Freire M.P., Espinoza-Ferrao S., Altamirano-Colina A., Echeverría-Espinoza P., Ramos-Medina M.J., Echeverría-Garcés G., Granda-Moncayo D., Jácome-Alvarado A., Andrade M.G., López-Cortés A. The pharmacoepigenetic paradigm in cancer treatment. Front Pharmacol. 2024. 15. 1381168. doi: 10.3389/fphar.2024.1381168.
57. Patel A., Pundkar A., Agarwal A., Gadkari C., Nagpal A.K., Kuttan N. A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management. Cureus. 2024. 16(9):e68784. doi: 10.7759/cureus.68784.
58. Qi CC., Xu LR., Zhao CJ. et al. Prevalence and risk factors of tuberculosis among people living with HIV/AIDS in China: a systematic review and meta-analysis. BMC Infect Dis. 2023. 23. 584. https://doi.org/10.1186/s12879-023-08575-4
59. Rodrigues T.S., Conti B.J., Fraga-Silva T.F.C., et al. Interplay between alveolar epithelial and dendritic cells and Mycobacterium tuberculosis. J Leukocyte Biol. 2020. 108. 1139–1156
60. Seth-Smith HMB., Imkamp F., Tagini F., Cuénod A., Hömke R., Jahn K., Tschacher A., Grendelmeier P., Bättig V., Erb S., Reinhard M., Rütimann G., et al. Discovery and Characterization of Mycobacterium basiliense sp. nov., a Nontuberculous Mycobacterium Isolated From Human Lungs. Front. Microbiol. 2019. 9. 3184. doi: 10.3389/fmicb.2018.03184
61. Shimeles E., Enquselassie F., Aseffa A., Tilahun M., Mekonen A., Wondimagegn G., Hailu T. Risk factors for tuberculosis: A case-control study in Addis Ababa, Ethiopia. PLoS One. 2019. 14(4):e0214235. doi: 10.1371/journal.pone.0214235.
62. Sultana Z.Z., Hoque F. U., Beyene J., Akhlak-Ul-Islam M., Khan M. H. R., Ahmed S., Hawlader D. H., & Hossain A. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC infectious diseases. 2021. 21(1). 51. https://doi.org/10.1186/s12879-020-05749-2
63. Velleca M., Malekinejad M., Miller C., Abascal Miguel L., Reeves H., Hopewell P., Fair E. The yield of tuberculosis contact investigation in low- and middle-income settings: a systematic review and meta-analysis. BMC Infect Dis. 2021. 21(1). 1011. doi: 10.1186/s12879-021-06609-3.
64. Vidyasagaran A.L., Readshaw A., Boeckmann M., Jarde A., Siddiqui F., Marshall A.M., Akram J., Golub J.E., Siddiqi K., Dogar O. Is Tobacco Use Associated With Risk of Recurrence and Mortality Among People With TB?: A Systematic Review and Meta-Analysis. Chest. 2024. 165(1). 22-47. doi: 10.1016/j.chest.2023.08.021.
65. Weiangkham D., Umnuaypornlert A., Saokaew S., Prommongkol S., Ponmark J. Effect of alcohol consumption on relapse outcomes among tuberculosis patients: A systematic review and meta-analysis. Front Public Health. 2022. 10:962809. doi: 10.3389/fpubh.2022.962809.
66. Whittaker E., López-Varela E., Broderick C., Seddon J.A. Examining the Complex Relationship Between Tuberculosis and Other Infectious Diseases in Children. Front Pediatr. 2019. 7. 233. doi: 10.3389/fped.2019.00233.
67. Windels E.M., Wampande E.M., Joloba M.L., Boom W.H., Goig G.A., Cox H., Hella J., Borrell S., Gagneux S., Brites D., Stadler T. HIV co-infection is associated with reduced Mycobacterium tuberculosis transmissibility in sub-Saharan Africa. PLoS Pathog. 2024. 20(5):e1011675. doi: 10.1371/journal.ppat.1011675.
68. Yerezhepov D., Gabdulkayum A., Akhmetova A., Kozhamkulov U., Rakhimova S., Kairov U., Zhunussova G., Kalendar R., Akilzhanova A. Pulmonary tuberculosis epidemiology and genetics in Kazakhstan. Front Public Health. 2024. 12. 1340673. doi: 10.3389/fpubh.2024.1340673.
69. Zeynali K.F., Khanjani S., Fardsanei F. et al. Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review. BMC Infect Dis. 2022. 22. 957. https://doi.org/10.1186/s12879-022-07944-9
Количество просмотров: 88
Категория статей:
Обзор литературы
Библиографическая ссылка
Kussainova A.A., Adilzhanov A.B., Adilgozhin M.S., Shalgumbayeva G.M., Derbissalina G.A., Bekbergenova Zh.B., Umbetzhanova A.T., Kozhakhmetova D.K., Zhokebaeva M.S., Shamshudinov T.M., Kassym L.T. Tuberculosis: prevalence, risk factors, and first-line drug resistance // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (5), pp. 177-187. doi 10.34689/SH.2024.26.5.021Похожие публикации:
PROBIOTICS AS ADDITIONAL TREATMENT OF RHEUMATOID ARTHRITIS. A REVIEW.
TUBERCULOSIS: PREVALENCE, RISK FACTORS, AND FIRST-LINE DRUG RESISTANCE
АКТУАЛЬНОЕ СОСТОЯНИЕ ПРОБЛЕМЫ НАРУШЕНИЯ РАЗВИТИЯ НЕРВНОЙ СИСТЕМЫ В РАННЕМ ВОЗРАСТЕ И ПОСЛЕДУЮЩЕЕ ВМЕШАТЕЛЬСТВО. ОБЗОР ЛИТЕРАТУРЫ.
PROGNOSTIC SIGNIFICANCE OF GENETIC TUMOR MARKERS IN THYROID NEOPLASMS: LITERATURE REVIEW
CHARACTERIZING THE ROLE OF ABCG5/G8 IN SITOSTEROLEMIA: DIAGNOSTIC CHALLENGES IN DIFFERENTIATING FROM FAMILIAL HYPERCHOLESTEROLEMIA